Biopharmaceutical company BerGenBio ASA (OSE:BGBIO) announced on Tuesday a collaboration with precision medicine company Tempus AI Inc (NASDAQ:TEM) to accelerate the development of its selective AXL kinase inhibitor, bemcentinib, in first-line non-small cell lung cancer (NSCLC) patients with STK11 mutations.
This partnership will provide BerGenBio access to Tempus' real-world clinical and molecular data to enhance its ongoing Phase 1b/2a BGBC016 trial. Tempus' AI-enabled platform will provide insights into the genomic landscape and treatment responses of NSCLC patients with STK11 mutations.
Upon completion of the BGBC016 study, the companies plan to present insights derived from the resulting data to regulatory agencies.
BerGenBio reveals preliminary safety data from Phase 1b BGBC016 study in first-line NSCLC patients
Liquidia and Pharmosa expand collaboration for inhaled treprostinil
Sanofi and Regeneron's Dupixent approved for COPD in China
Alvotech launches confirmatory study for Entyvio biosimilar
Merck's KEYTRUDA receives new approvals in Japan for lung and urothelial cancers
Innate Pharma receives FDA clearance of IND for IPH4502, a Nectin-4 targeting ADC for solid tumours
Intas Pharmaceuticals reports positive opinion for HETRONIFLY in Europe
Insilico Medicine reveals positive preliminary results from ISM001-055Phase IIa clinical trial
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi